Dataset Information

Mirdametinib treatment for the osteofibrous dysplasia RASopathy

ABSTRACT: The goal of this study was to investigate the molecular response of primary cells cultured from the pseudarthrosis sites of Osteofibrous Dysplasia patients following 24h treatment with vehicle (DMSO), capmatinib (10uM, Catalog# S2788, Selleck Chemicals, USA), selumetinib (5uM, Catalog# S1008, Selleck Chemicals, USA), or mirdametinib (100nM, Catalog# S1036, Selleck Chemicals, USA). Transcriptional changes were

ORGANISM(S): Homo sapiens

PROVIDER: GSE305253 | GEO | 2026/02/11

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:High-throughput transcriptomics (HTTr) uses gene expression profiling to characterize the biological activity of chemicals in in vitro cell-based test systems. As an extension of a previous study testing 44 chemicals, HTTr was used to screen an additional 1751 unique chemicals from the EPA’s ToxCast collection in MCF7 cells using eight concentrations and an exposure duration of 6 hours. We hypothesized that concentration-response modeling of signature scores could be used to identify putative molecular targets and cluster chemicals with similar bioactivity. Clustering and enrichment analyses were conducted based on signature catalog annotations and ToxPrint chemotypes to facilitate molecular target prediction and grouping of chemicals with similar bioactivity profiles. Enrichment analysis based on signature catalog annotation identified known mechanisms-of-action (MeOAs) associated with well-studied chemicals and generated putative MeOAs for other active chemicals. Chemicals with predicted MeOAs included those targeting estrogen receptor (ER), glucocorticoid receptor (GR), retinoic acid receptor (RAR), the NRF2/KEAP/ARE pathway, AP-1 activation and others. Using reference chemicals for ER modulation, the study demonstrated that HTTr in MCF7 cells was able to stratify chemicals in terms of agonist potency, distinguish ER agonists from antagonists, and cluster chemicals with similar activities as predicted by the ToxCast ER Pathway model. Uniform manifold approximation and projection (UMAP) embedding of signature-level results identified novel ER modulators with no ToxCast ER Pathway model predictions. Finally, UMAP combined with ToxPrint chemotype enrichment was used to explore the biological activity of structurally-related chemicals. The study demonstrates that HTTr can be used to inform chemical risk assessment by determining in vitro points-of-departure, predicting chemicals’ molecular mechanism(s)-of-action (MeOA) and grouping chemicals with similar bioactivity profiles.

Dataset Information

Mirdametinib treatment for the osteofibrous dysplasia RASopathy

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets